RxSight, Inc. Shareholders Urged to Reach Out to Levi & Korsinsky by September 22, 2025 to Explore Their Rights – RXST
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2025
0mins
Should l Buy RXST?
Source: Globenewswire
Class Action Lawsuit: A class action securities lawsuit has been filed against RxSight, Inc. for alleged securities fraud affecting investors between May 7, 2024, and July 8, 2025.
Allegations Against RxSight: The complaint claims that RxSight misled investors about its sales performance and product demand, resulting in a failure to meet financial guidance for fiscal year 2025.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RXST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RXST
Wall Street analysts forecast RXST stock price to rise
9 Analyst Rating
1 Buy
6 Hold
2 Sell
Hold
Current: 7.800
Low
8.00
Averages
10.25
High
14.00
Current: 7.800
Low
8.00
Averages
10.25
High
14.00
About RXST
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
- Mixed Market Performance: U.S. stocks exhibited mixed results on Monday, with the Nasdaq Composite gaining over 50 points and rising 0.29%, while the Dow Jones fell 0.19% to 49,411.94, indicating market volatility and investor caution.
- Biopharma Surge: Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares surged 20% to $10.77 after reporting a projected 2025 OJEMDA net product revenue of $155.4 million, a 172% year-over-year increase, highlighting strong market demand and growth potential.
- FDA Response Impact: Atara Biotherapeutics Inc (NASDAQ:ATRA) shares plummeted 53% to $6.41 following a Complete Response Letter from the FDA citing concerns over clinical trial adequacy, raising investor worries about the company's future prospects.
- Sector Sentiment Fluctuations: Financial stocks dipped by 1.1% while consumer staples rose by 1%, reflecting differing investor confidence across sectors, which may influence future investment strategies and market trends.
See More
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
- Stock Surge: Planet Labs PBC's announcement of a multi-year nine-figure agreement with the Swedish Armed Forces led to a 7% increase in share price to $24.29 on Monday, reflecting strong market confidence in the company's long-term contracts.
- Revenue Outlook Boost: Day One Biopharmaceuticals Inc reported preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year-over-year, indicating robust growth potential in the biopharmaceutical sector that may attract more investor interest.
- Market Dynamics: Amid a broader decline in U.S. stocks, Wheels Up Experience Inc saw its shares jump 30.2% to $0.89, suggesting a market reassessment of its business model, potentially providing support for future financing and expansion.
- Increased Demand for Safe Assets: Growing concerns about Federal Reserve independence have led investors to shift towards safe-haven assets like gold, driving up precious metals stocks, which reflects market sensitivity to economic uncertainties and a preference for secure investments.
See More
RxSight Expects Q4 2025 Revenue of $32.6 Million, Appoints CFO
- Revenue Forecast Upgrade: RxSight anticipates Q4 2025 revenue to reach approximately $32.6 million, exceeding analysts' expectations of $27.53 million, indicating strong market performance and growth potential for the company.
- Annual Revenue Outlook: Preliminary unaudited revenue for fiscal year 2025 is expected to be around $134.5 million, up from the November guidance of $125 million to $130 million, reflecting robust business growth and increased market demand.
- Executive Appointment: The company has appointed Mark Wilterding as Chief Financial Officer, effective January 11, 2026, bringing over 25 years of financial leadership experience that will provide valuable industry insights and strategic direction.
- Financial Reporting Schedule: RxSight plans to announce audited full-year financial results and 2026 guidance in conjunction with its Q4 earnings release, expected to provide investors with clearer future outlooks.
See More
RxSight Reports $134.5M Revenue for 2025, Announces CFO Transition
- Revenue Growth: Preliminary unaudited revenue for 2025 is expected to be approximately $134.5 million, exceeding prior guidance of $125 to $130 million, indicating strong performance in the ophthalmic medical device market.
- Procedure Volume Increase: The sale of 28,611 Light Adjustable Lenses (LAL) in Q4 represents a 10% increase compared to Q3 2025, reflecting positive progress in surgical volume recovery.
- Device Installation Expansion: As of December 31, 2025, the company has installed 1,134 Light Delivery Devices (LDD), which not only enhances market penetration but also lays a solid foundation for future growth.
- Executive Transition: Mark Wilterding has been appointed Chief Financial Officer effective January 11, 2026, and with his extensive experience in Medtech, he is expected to drive further advancements in financial management and operational excellence for the company.
See More
RxSight to Present at J.P. Morgan Healthcare Conference on January 13, 2026
- Conference Participation: RxSight is scheduled to present at the J.P. Morgan Healthcare Conference on January 13, 2026, showcasing its ability to provide high-quality customized vision post-cataract surgery, which is expected to attract attention from investors and the healthcare industry.
- Technology Highlight: The RxSight Light Adjustable Lens system is the only intraocular lens technology that can be adjusted after surgery, enabling personalized vision for patients, thereby reinforcing its leading position in the ophthalmic medical device market.
- Investor Relations: The conference will offer live and archived webcasts, facilitating access to the latest information for investors and enhancing interaction between the company and its stakeholders, thereby improving market transparency.
- Strategic Significance: By participating in a top industry conference, RxSight not only showcases its innovative technology but also potentially paves the way for future financing and collaboration opportunities, further driving growth in the rapidly evolving ophthalmic device market.
See More
RxSight to Present at J.P. Morgan Healthcare Conference on January 13, 2026
- Conference Participation: RxSight is scheduled to present at the J.P. Morgan Healthcare Conference on January 13, 2026, at 3:45 PM Pacific Time, showcasing its ability to provide high-quality customized vision post-cataract surgery.
- Technology Introduction: The RxSight Light Adjustable Lens system is the only intraocular lens technology that can be adjusted after surgery, enabling personalized customization to enhance patients' visual quality.
- Investor Relations: The conference will feature live and archived webcasts, allowing investors and stakeholders to stay informed about RxSight's latest developments and technological innovations, thereby enhancing interaction between the company and its investors.
- Market Positioning: By participating in this conference, RxSight not only demonstrates its leadership in the ophthalmic medical device sector but also further solidifies its strategic position in the rapidly evolving healthcare market.
See More
U.S. Stocks Mixed; Day One Biopharmaceuticals Shares Surge 20%
- Mixed Market Performance: U.S. stocks exhibited mixed results on Monday, with the Nasdaq Composite gaining over 50 points and rising 0.29%, while the Dow Jones fell 0.19% to 49,411.94, indicating market volatility and investor caution.
- Biopharma Surge: Day One Biopharmaceuticals Inc (NASDAQ:DAWN) shares surged 20% to $10.77 after reporting a projected 2025 OJEMDA net product revenue of $155.4 million, a 172% year-over-year increase, highlighting strong market demand and growth potential.
- FDA Response Impact: Atara Biotherapeutics Inc (NASDAQ:ATRA) shares plummeted 53% to $6.41 following a Complete Response Letter from the FDA citing concerns over clinical trial adequacy, raising investor worries about the company's future prospects.
- Sector Sentiment Fluctuations: Financial stocks dipped by 1.1% while consumer staples rose by 1%, reflecting differing investor confidence across sectors, which may influence future investment strategies and market trends.
See More
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
- Stock Surge: Planet Labs PBC's announcement of a multi-year nine-figure agreement with the Swedish Armed Forces led to a 7% increase in share price to $24.29 on Monday, reflecting strong market confidence in the company's long-term contracts.
- Revenue Outlook Boost: Day One Biopharmaceuticals Inc reported preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year-over-year, indicating robust growth potential in the biopharmaceutical sector that may attract more investor interest.
- Market Dynamics: Amid a broader decline in U.S. stocks, Wheels Up Experience Inc saw its shares jump 30.2% to $0.89, suggesting a market reassessment of its business model, potentially providing support for future financing and expansion.
- Increased Demand for Safe Assets: Growing concerns about Federal Reserve independence have led investors to shift towards safe-haven assets like gold, driving up precious metals stocks, which reflects market sensitivity to economic uncertainties and a preference for secure investments.
See More
RxSight Expects Q4 2025 Revenue of $32.6 Million, Appoints CFO
- Revenue Forecast Upgrade: RxSight anticipates Q4 2025 revenue to reach approximately $32.6 million, exceeding analysts' expectations of $27.53 million, indicating strong market performance and growth potential for the company.
- Annual Revenue Outlook: Preliminary unaudited revenue for fiscal year 2025 is expected to be around $134.5 million, up from the November guidance of $125 million to $130 million, reflecting robust business growth and increased market demand.
- Executive Appointment: The company has appointed Mark Wilterding as Chief Financial Officer, effective January 11, 2026, bringing over 25 years of financial leadership experience that will provide valuable industry insights and strategic direction.
- Financial Reporting Schedule: RxSight plans to announce audited full-year financial results and 2026 guidance in conjunction with its Q4 earnings release, expected to provide investors with clearer future outlooks.
See More
RxSight Reports $134.5M Revenue for 2025, Announces CFO Transition
- Revenue Growth: Preliminary unaudited revenue for 2025 is expected to be approximately $134.5 million, exceeding prior guidance of $125 to $130 million, indicating strong performance in the ophthalmic medical device market.
- Procedure Volume Increase: The sale of 28,611 Light Adjustable Lenses (LAL) in Q4 represents a 10% increase compared to Q3 2025, reflecting positive progress in surgical volume recovery.
- Device Installation Expansion: As of December 31, 2025, the company has installed 1,134 Light Delivery Devices (LDD), which not only enhances market penetration but also lays a solid foundation for future growth.
- Executive Transition: Mark Wilterding has been appointed Chief Financial Officer effective January 11, 2026, and with his extensive experience in Medtech, he is expected to drive further advancements in financial management and operational excellence for the company.
See More
RxSight to Present at J.P. Morgan Healthcare Conference on January 13, 2026
- Conference Participation: RxSight is scheduled to present at the J.P. Morgan Healthcare Conference on January 13, 2026, showcasing its ability to provide high-quality customized vision post-cataract surgery, which is expected to attract attention from investors and the healthcare industry.
- Technology Highlight: The RxSight Light Adjustable Lens system is the only intraocular lens technology that can be adjusted after surgery, enabling personalized vision for patients, thereby reinforcing its leading position in the ophthalmic medical device market.
- Investor Relations: The conference will offer live and archived webcasts, facilitating access to the latest information for investors and enhancing interaction between the company and its stakeholders, thereby improving market transparency.
- Strategic Significance: By participating in a top industry conference, RxSight not only showcases its innovative technology but also potentially paves the way for future financing and collaboration opportunities, further driving growth in the rapidly evolving ophthalmic device market.
See More
RxSight to Present at J.P. Morgan Healthcare Conference on January 13, 2026
- Conference Participation: RxSight is scheduled to present at the J.P. Morgan Healthcare Conference on January 13, 2026, at 3:45 PM Pacific Time, showcasing its ability to provide high-quality customized vision post-cataract surgery.
- Technology Introduction: The RxSight Light Adjustable Lens system is the only intraocular lens technology that can be adjusted after surgery, enabling personalized customization to enhance patients' visual quality.
- Investor Relations: The conference will feature live and archived webcasts, allowing investors and stakeholders to stay informed about RxSight's latest developments and technological innovations, thereby enhancing interaction between the company and its investors.
- Market Positioning: By participating in this conference, RxSight not only demonstrates its leadership in the ophthalmic medical device sector but also further solidifies its strategic position in the rapidly evolving healthcare market.
See More
